Lupin Limited

LUPIN · NSE

Public Market Listing

LUPINNSE

NSE primary exchange listing

Live quotes, historical charts, and market capitalization for Lupin Limited are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(3 total)
3Total Assets
2Approved
1Phase 3 / Filed
0Phase 1–2 / Early
5Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Approved
beta-2 adrenergic receptor
Asthma
Approved
VEGF-AMonoclonal antibody
Age-Related Macular DegenerationDiabetic Macular Edema
Phase 3
GLP-1 receptorPeptide
ObesityType 2 Diabetes

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
June 2027 (1)
BofanglutidePhase 3Obesity/Overweight in Adult
Est. primary completion 2027-06-30 · NCT07150975 · CT.gov ↗
What to watch
November 2027 (1)
BofanglutidePhase 3Obstructive Sleep Apnea (OSA)
Est. primary completion 2027-11-14 · NCT07493057 · CT.gov ↗
What to watch
2028 (1)
September 2028 (1)
BofanglutidePhase 3Obstructive Sleep Apnea (OSA)
Est. primary completion 2028-09-28 · NCT07501832 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

3 September 2026Licensing dealGZR18 (bofanglutide)Gan & Lee licenses bofanglutide to Menarini for Europe (39 countries)
Gan & Lee Pharmaceuticals; The Menarini Group · Source ↗
12 June 2026Topline resultGZR18GRADUAL-1: bofanglutide meets primary endpoint in China Phase 3
Gan & Lee Pharmaceuticals · Source ↗

Financial reports

Annual history (1 year)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-FY$3.2B$233M——report ↗